• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫检查点阻断抗肿瘤治疗中的调节性 T 细胞。

Regulatory T cells in immune checkpoint blockade antitumor therapy.

机构信息

Department of Colorectal Surgery, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Department of Thoracic Surgery, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

出版信息

Mol Cancer. 2024 Nov 8;23(1):251. doi: 10.1186/s12943-024-02156-y.

DOI:10.1186/s12943-024-02156-y
PMID:39516941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11545879/
Abstract

Regulatory T cells (Tregs), an essential component of the human immune system, are a heterogeneous group of T lymphocytes with the ability to suppress immune responses and maintain immune homeostasis. Recent evidence indicates that Tregs may impair antitumor immunity and facilitate cancer progression by weakening functions of effector T cells (Teffs). Consequently, targeting Tregs to eliminate them from tumor microenvironments to improve Teffs' activity could emerge as an effective strategy for cancer immunotherapy. This review outlines the biology of Tregs, detailing their origins, classification, and crucial markers. Our focus lies on the complex role of Tregs in cancer's development, progression and treatment, particularly on their suppressive role upon antitumor responses via multiple mechanisms. We delve into Tregs' involvement in immune checkpoint blockade (ICB) therapy, their dual effect on cancer immunotherapy and their potential biomarkers for ICB therapy effectiveness. We also summarize advances in the therapies that adjust Tregs to optimize ICB therapy, which may be crucial for devising innovative cancer treatment strategies.

摘要

调节性 T 细胞(Tregs)是人体免疫系统的重要组成部分,是一群具有抑制免疫反应和维持免疫稳态能力的异质性 T 淋巴细胞。最近的证据表明,Tregs 通过削弱效应 T 细胞(Teffs)的功能可能会损害抗肿瘤免疫并促进癌症进展。因此,靶向 Tregs 以消除其在肿瘤微环境中的作用,从而提高 Teffs 的活性,可能成为癌症免疫治疗的有效策略。本综述概述了 Tregs 的生物学特性,详细介绍了其起源、分类和关键标志物。我们的重点是 Tregs 在癌症发展、进展和治疗中的复杂作用,特别是它们通过多种机制对抗肿瘤反应的抑制作用。我们深入探讨了 Tregs 在免疫检查点阻断(ICB)治疗中的参与,它们对癌症免疫治疗的双重影响以及它们作为 ICB 治疗效果的潜在生物标志物。我们还总结了调节 Tregs 以优化 ICB 治疗的疗法进展,这对于制定创新的癌症治疗策略可能至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01a/11545879/31d90e9d86b5/12943_2024_2156_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01a/11545879/f88df05be5e2/12943_2024_2156_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01a/11545879/c29eeda5ba25/12943_2024_2156_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01a/11545879/86606f99cb78/12943_2024_2156_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01a/11545879/31d90e9d86b5/12943_2024_2156_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01a/11545879/f88df05be5e2/12943_2024_2156_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01a/11545879/c29eeda5ba25/12943_2024_2156_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01a/11545879/86606f99cb78/12943_2024_2156_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01a/11545879/31d90e9d86b5/12943_2024_2156_Fig4_HTML.jpg

相似文献

1
Regulatory T cells in immune checkpoint blockade antitumor therapy.免疫检查点阻断抗肿瘤治疗中的调节性 T 细胞。
Mol Cancer. 2024 Nov 8;23(1):251. doi: 10.1186/s12943-024-02156-y.
2
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.癌症治疗中的免疫检查点抑制剂:以 T 调节细胞为重点。
Immunol Cell Biol. 2018 Jan;96(1):21-33. doi: 10.1111/imcb.1003. Epub 2017 Nov 17.
3
Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.调节性 T 细胞作为癌症治疗中 PD-1/PD-L1 阻断后发生超进展性疾病的关键触发因素和潜在靶点。
Int Immunopharmacol. 2024 May 10;132:111934. doi: 10.1016/j.intimp.2024.111934. Epub 2024 Apr 3.
4
Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.癌症中调节性T细胞的代谢调控:免疫治疗的机遇
Trends Cancer. 2017 Aug;3(8):583-592. doi: 10.1016/j.trecan.2017.06.005. Epub 2017 Jul 14.
5
Role of heterogeneous regulatory T cells in the tumor microenvironment.异质性调节性 T 细胞在肿瘤微环境中的作用。
Pharmacol Res. 2020 Mar;153:104659. doi: 10.1016/j.phrs.2020.104659. Epub 2020 Jan 23.
6
The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies.调节性 T 细胞对癌症免疫和免疫检查点抑制剂治疗效果的影响。
Front Immunol. 2021 Feb 26;12:625783. doi: 10.3389/fimmu.2021.625783. eCollection 2021.
7
Remodeling of the tumor microenvironment via disrupting Blimp1 effector Treg activity augments response to anti-PD-1 blockade.通过破坏 Blimp1 效应性 Treg 活性重塑肿瘤微环境可增强对抗 PD-1 封锁的反应。
Mol Cancer. 2021 Nov 20;20(1):150. doi: 10.1186/s12943-021-01450-3.
8
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.调节性 T 细胞浸润肿瘤的机制:对创新免疫精准治疗的启示。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002591.
9
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.癌症免疫疗法中的检查点抑制剂可能会由于 Treg 稳态的丧失而导致自身免疫性不良反应。
Semin Cancer Biol. 2020 Aug;64:29-35. doi: 10.1016/j.semcancer.2019.01.006. Epub 2019 Feb 1.
10
Expression of costimulatory and inhibitory receptors in FoxP3 regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches.肿瘤微环境中 FoxP3 调节性 T 细胞中共刺激和共抑制受体的表达:对联合免疫治疗方法的影响。
Adv Cancer Res. 2019;144:193-261. doi: 10.1016/bs.acr.2019.05.001. Epub 2019 Jun 6.

引用本文的文献

1
Molecular Targets for Pharmacotherapy of Head and Neck Squamous Cell Carcinomas.头颈部鳞状细胞癌药物治疗的分子靶点
Curr Issues Mol Biol. 2025 Aug 1;47(8):609. doi: 10.3390/cimb47080609.
2
Immune Evasion in Head and Neck Squamous Cell Carcinoma: Roles of Cancer-Associated Fibroblasts, Immune Checkpoints, and Mutations in the Tumor Microenvironment.头颈部鳞状细胞癌中的免疫逃逸:肿瘤相关成纤维细胞、免疫检查点及肿瘤微环境中突变的作用
Cancers (Basel). 2025 Aug 7;17(15):2590. doi: 10.3390/cancers17152590.
3
An Fe(III)-covalent organic framework (COF)-sorafenib nanoplatform induces chemo-ferroptosis for enhanced hepatocellular carcinoma immunotherapy.

本文引用的文献

1
Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).非黑色素瘤皮肤癌(NMSC)中的肿瘤微环境免疫检查点和细胞景观。
Cells. 2024 Sep 26;13(19):1615. doi: 10.3390/cells13191615.
2
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance.癌症免疫治疗耐药的机制、联合治疗及生物标志物。
Cell Commun Signal. 2024 Jun 19;22(1):338. doi: 10.1186/s12964-024-01711-w.
3
Interruption of the intratumor CD8 T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy.
一种铁(III)共价有机框架(COF)-索拉非尼纳米平台诱导化学铁死亡以增强肝细胞癌免疫治疗。
Mater Today Bio. 2025 Jul 26;34:102135. doi: 10.1016/j.mtbio.2025.102135. eCollection 2025 Oct.
4
Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma.基于纳米材料的黑色素瘤协同疗法的临床转化机制进展与挑战
Front Cell Dev Biol. 2025 Jul 25;13:1648379. doi: 10.3389/fcell.2025.1648379. eCollection 2025.
5
Dysregulated Cholesterol Metabolism and Its Impact on the Tumour Immune Response in Colorectal Cancer.胆固醇代谢失调及其对结直肠癌肿瘤免疫反应的影响
J Cell Mol Med. 2025 Aug;29(15):e70789. doi: 10.1111/jcmm.70789.
6
Identification of cell adhesion related signature for molecular subtyping and prognostic prediction in acute myeloid leukemia.急性髓系白血病中用于分子亚型分型和预后预测的细胞粘附相关特征识别
Discov Oncol. 2025 Jul 23;16(1):1397. doi: 10.1007/s12672-025-03208-5.
7
CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies.基于嵌合抗原受体T细胞(CAR-T)疗法的创新在当代抗肿瘤治疗增强方面的应用。
Front Immunol. 2025 Jul 2;16:1622433. doi: 10.3389/fimmu.2025.1622433. eCollection 2025.
8
T cells in cancer: mechanistic insights and therapeutic advances.癌症中的T细胞:机制洞察与治疗进展
Biomark Res. 2025 Jul 15;13(1):97. doi: 10.1186/s40364-025-00807-w.
9
Tumor Microenvironment, Inflammation, and Inflammatory Prognostic Indices in Diffuse Large B-Cell Lymphomas: A Narrative Review.弥漫性大B细胞淋巴瘤中的肿瘤微环境、炎症及炎症性预后指标:一篇叙述性综述
Int J Mol Sci. 2025 Jun 13;26(12):5670. doi: 10.3390/ijms26125670.
10
High intratumoral heterogeneity in clear cell renal cell carcinoma is associated with reduced immune response and survival.透明细胞肾细胞癌中高肿瘤内异质性与免疫反应降低和生存率降低相关。
Transl Androl Urol. 2025 May 30;14(5):1190-1203. doi: 10.21037/tau-2024-741. Epub 2025 May 27.
阻断肿瘤内 CD8 T 细胞:Treg 细胞串扰可提高 PD-1 免疫治疗的疗效。
Cancer Cell. 2024 Jun 10;42(6):1051-1066.e7. doi: 10.1016/j.ccell.2024.05.013.
4
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review.调节性 T 细胞在肿瘤微环境中的潜在抗肿瘤作用:综述。
J Transl Med. 2024 Mar 20;22(1):293. doi: 10.1186/s12967-024-05104-y.
5
Targeting tumor-infiltrating tregs for improved antitumor responses.针对肿瘤浸润性 Tregs 以提高抗肿瘤反应。
Front Immunol. 2024 Mar 4;15:1325946. doi: 10.3389/fimmu.2024.1325946. eCollection 2024.
6
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.抗 TIGIT 抗体通过髓系细胞和 T 细胞增强 PD-L1 阻断作用。
Nature. 2024 Mar;627(8004):646-655. doi: 10.1038/s41586-024-07121-9. Epub 2024 Feb 28.
7
Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells.乳酸调节 RNA 剪接以促进肿瘤浸润调节性 T 细胞中 CTLA-4 的表达。
Immunity. 2024 Mar 12;57(3):528-540.e6. doi: 10.1016/j.immuni.2024.01.019. Epub 2024 Feb 27.
8
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.伊匹单抗和纳武单抗联合蒽环类化疗药物治疗转移性激素受体阳性乳腺癌:一项随机2b期试验
J Immunother Cancer. 2024 Jan 19;12(1):e007990. doi: 10.1136/jitc-2023-007990.
9
Non-IL-2-blocking anti-CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti-CTLA-4 therapy.非阻断 IL-2 的抗 CD25 抗体通过耗尽 Tregs 抑制肿瘤生长,并与抗 CTLA-4 治疗具有协同作用。
Int J Cancer. 2024 Apr 1;154(7):1285-1297. doi: 10.1002/ijc.34823. Epub 2024 Jan 5.
10
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.XTX101,一种肿瘤激活、Fc 增强的抗 CTLA-4 单克隆抗体,在癌症小鼠模型中表现出肿瘤生长抑制和肿瘤选择性药效学。
J Immunother Cancer. 2023 Dec 12;11(12):e007785. doi: 10.1136/jitc-2023-007785.